Alkynylnicotinamide‐Based Compounds as ABL1 Inhibitors with Potent Activities against Drug‐Resistant CML Harboring ABL1(T315I) Mutant Kinase
Sign Up to like & getrecommendations! Published in 2018 at "ChemMedChem"
DOI: 10.1002/cmdc.201700829
Abstract: The introduction of imatinib into the clinical scene revolutionized the treatment of chronic myelogenous leukemia (CML). The overall eight‐year survival rate for CML has increased from about 6 % in the 1970s to over 90 % in… read more here.
Keywords: abl1 t315i; cml; kinase; drug resistant ... See more keywords